Patients with advanced melanoma who receive lifileucel (Amtagvi) — the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy — appear to have a relatively smooth post-discharge course, according to a new retrospective analysis published in JCO Oncology Practice. Researchers at Memorial Sloan Kettering Cancer Center reviewed records of 51 patients discharged after lifileucel treatment between October 2020 and October 2024, finding that serious treatment-related complications after leaving the hospital were uncommon.

Notably, new severe adverse events tended to emerge weeks to months after discharge — not in the immediate post-discharge window — suggesting that the intensive, early monitoring protocols borrowed from CAR-T therapy may not be necessary for TIL therapy patients. Clinicians noted that individual patient status at discharge (blood counts, mobility, oxygen needs) could guide tailored follow-up plans.

By the Numbers:

• 3.9% of patients developed a new grade 3 treatment-related adverse event post-discharge
• 7.8% were readmitted due to treatment-related toxicity (median time to readmission: 49 days)
• 24% required outpatient blood transfusions
• 22% were readmitted for any reason; most readmissions were due to disease progression, not toxicity
• Median hospital stay for initial treatment: 19 days

Why it matters: These findings challenge the assumption that TIL therapy patients need the same rigorous post-discharge monitoring as CAR-T recipients. With more flexible follow-up, patients — many of whom travel long distances for treatment — could have care plans better suited to their lives, without compromising safety.